Access cutting-edge iga monoclonal gammopathy of undetermined significance treatment through this clinical trial at a research site in Seattle. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Seattle location
Preparing your pre-screening questions…
Access iga monoclonal gammopathy of undetermined significance specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related iga monoclonal gammopathy of undetermined significance treatment provided free
Check if you qualify for this iga monoclonal gammopathy of undetermined significance clinical trial in Seattle, WA
No-Cost Study Care
Local to Seattle
Convenient for WA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgA monoclonal gammopathy of undetermined significance (MGUS). Rifaximin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's DNA and may kill cancer cells or precancerous cells like those found with MGUS. Giving rifaximin may kill more precancerous cells in patients with IgA MGUS.
Sponsor: Fred Hutchinson Cancer Center
Yes, this clinical trial (NCT07209371) has an active research site in Seattle, WA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for iga monoclonal gammopathy of undetermined significance treatment options in Seattle, WA, this clinical trial (NCT07209371) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Seattle research site is actively enrolling participants for this clinical trial. You'll receive care from experienced iga monoclonal gammopathy of undetermined significance specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all iga monoclonal gammopathy of undetermined significance clinical trials near you to find additional studies recruiting in your area.
See all multiple myeloma clinical trials recruiting in Seattle — not just this study.
Browse Multiple Myeloma Trials in Seattle →